Table 1.

Analysis of the time to viral clearance with adjustments for age and gender.

	Mean of Length of Hospital Stay	Mortality Rate	Time to Viral Clearance Median (IQR)	HR	95% CI	p-Value
Treatment groups
Symptomatic treatment	9.4		6 (6–10)	Ref
Favipiravir	9.1		7 (4–11)	1.97	(1.74–2.23)	0.000
Bamlanivimab	5.4	3/67 (4.4%)	6 (4–9)	5.56	(4.07–7.58)	0.000
Sex
Female	10.0		6 (6–14)	Ref
Male	9.0		6 (6–9)	1.15	(1.04–1.27)	0.007
Age				0.996	(0.993–0.999)	0.012